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Abstract 
We have previously shown that patients with primary progressive multiple sclerosis 
(MS) have significantly elevated plasma levels of antibody to GM3 ganglioside 
compared to patients with relapsing-remitting MS, healthy subjects and patients with 
other neurological diseases. Anti-GM3 antibody levels were elevated also in patients 
with secondary progressive MS but to a lesser extent than in primary progressive MS. 
As gangliosides are particularly enriched in the axonal membrane, these findings 
suggested that antiganglioside immune responses might contribute to the axonal 
damage in progressive forms of MS. The present study was performed to determine 
whether peripheral blood T cell responses to GM3 are also increased in progressive 
MS. Blood was collected from 98 untreated patients with MS (40 with relapsing-
remitting, 27 with secondary progressive and 31 with primary progressive MS), 50 
healthy subjects and 24 patients with other disorders of the CNS, and reactivity to 
GM1, GM3, GD1a, GD1b, GD3, GT1b, GQ1b and sulphatide was assessed by 6-day 
T cell proliferation assays. Increased T cell reactivity to GM3 and GQ1b occurred 
significantly more often in patients with primary progressive MS than in healthy 
subjects and patients with other CNS diseases. These findings suggest that 
ganglioside-specific T cells may contribute to the axonal damage in primary 
progressive MS.  
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Introduction 
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the 
central nervous system (CNS) and is a common cause of persistent disability in young 
adults. Typically MS has a relapsing-remitting course with clinical attacks followed 
by some improvement and attack-free intervals. Often, however, this initially 
relapsing-remitting course eventually changes to a progressive one in which 
progressive neurological deterioration occurs independently of relapses (secondary 
progressive MS). In 10–20% of cases the disease has a progressive course from onset 
(primary progressive MS). An immune attack directed primarily at axonal antigens 
rather than at myelin antigens could explain the progressive course of this form of 
MS. The inherent capacity for CNS axonal regeneration is much more limited than the 
capacity for CNS remyelination, which is likely to contribute to the clinical recovery 
from attacks of relapsing-remitting MS. It is also possible that the transition from 
relapsing-remitting to secondary progressive MS may involve the spreading of the 
immune response from myelin antigens to axonal antigens.1 
Gangliosides constitute an important group of axonal antigens and are also minor 
constituents of myelin. They are particularly enriched in the plasma membranes of 
axons and neuronal cell bodies compared to the plasma membranes of most other cell 
types.2 Gangliosides are glycolipids with one or more sialic acid residues in their 
oligosaccharide chains, and have been incriminated as potential target antigens in 
several diseases of the human peripheral nervous system. Convincing evidence that 
immune responses against gangliosides may indeed cause axonal degeneration has 
been provided by the induction of experimental sensory ataxic neuropathy in rabbits 
by immunization with GD1b, a ganglioside found in dorsal root ganglion neurons and 
dorsal root axons. 3 
Several studies have found increased antiganglioside antibody levels in the sera 
and/or cerebrospinal fluid (CSF) of patients with MS.4, 5, 6, 7, 8, 9, 10, 11, 12, 13 Acarin et al. 
11 and Sadatipour et al. 12 compared the levels among the subtypes of MS and showed 
increased antiganglioside antibody levels in patients with primary progressive MS. 
Several studies have also demonstrated increased peripheral blood T lymphocyte 
responses to mixed ganglioside preparations in patients with MS. 14, 15, 16, 17, 18 
However, there have been no studies comparing T cell reactivity to individual 
gangliosides among the relapsing-remitting, secondary progressive and primary 
progressive forms of MS. The present study was performed to determine the T cell 
responses to individual gangliosides in the different forms of MS. We found increased 
peripheral blood T cell proliferative responses to GM3 and GQ1b gangliosides in 
patients with primary progressive MS. 
Materials and methods 
Patients and control subjects 
The subjects of this study consisted of 98 patients with MS, 50 healthy control 
subjects and 24 patients with other CNS diseases. All the patients with MS met the 
criteria of Poser et al.19 for clinically definite or laboratory-supported definite MS. All 
except 4 patients with MS also met the criteria of McDonald et al. 20 for MS; these 4 
could not be assessed against these criteria because magnetic resonance imaging scans 
were not available for inspection. Of the MS patients, 40 had relapsing-remitting MS, 
27 had secondary progressive MS and 31 had primary progressive MS, as defined by 
the criteria of Lublin and Reingold. 21 MS patients had not received corticosteroid or 
other immunomodulatory therapies for at least 2 months prior to being studied except 
for 1 patient who ceased interferon  therapy 5 weeks before being studied. Patients 
with other CNS diseases had the following diagnoses: cerebral infarction (5), epilepsy 
with associated cerebral pathology (5), motor neuron disease (4), brain haemorrhage 
(3), spinal cord infarction/ischaemic myelopathy (2), intracranial meningioma (1), 
coeliac disease with progressive cerebellar ataxia (one), viral encephalitis (1), Krabbe 
leukodystrophy (1) and neurofibromatosis type I with optic nerve glioma (1). This 
study was approved by the Human Research Ethics Committee of the Royal Brisbane 
Hospital and the Medical Research Ethics Committee of The University of 
Queensland. 
Tissue typing 
Genomic DNA was prepared from either Epstein-Barr-virus transformed 
lymphoblastoid cell lines or from heparinized whole blood by either 
chloroform/phenol extraction, or by overnight digestion using sodium dodecyl 
sulphate/proteinase K, followed by salting out of high molecular weight DNA. HLA-
DRB1 tissue typing was performed using SSP HLA typing kits (Dynal Biotech, Oslo, 
Norway). 
Antigens 
Bovine gangliosides GM1, GM3, GD1a, GD1b, GD3, GT1b and GQ1b and 
sulphatide were purchased from Sigma (St. Louis, USA). Their structures are shown 
in Fig. 1. To determine the optimal concentration of ganglioside for use in the 
proliferation assays, cells from 20 patients with MS and 20 healthy subjects were 
initially tested in culture at concentrations ranging from 800 to 0.005 ng/ml.  
 
 
Fig. 1. Structures of gangliosides and sulphatide used in this study. Glc, glucose; Gal, galactose; 
GalNAc, N-acetylgalactosamine; NeuAc, N-acetylneuraminic acid; cer, ceramide. 
Proliferation assays 
Heparinized peripheral blood (~60 ml) was collected by venepuncture from each 
subject after informed written consent had been obtained. Peripheral blood 
mononuclear cells were separated from blood by centrifugation through Histopaque 
(Sigma Chemical, St. Louis, USA) and washed twice. Proliferation assays were 
prepared as 200 l/well, 105 cells/well quadruplicate cultures with and without test 
antigens in 96-well round-bottomed microtitre plates (Nunc, Denmark) in RPMI-1640 
media supplemented with 10% heat-inactivated pooled human serum, 2 mM -
glutamine and 10 mM HEPES buffer. Cultures were incubated for 6 days, with 0.5 
Ci [3H]thymidine being added during the last 18 h. Cultures were harvested and 
thymidine uptake was measured in c.p.m. (counts per minute) in a plate counter 
(LKB). For each ganglioside tested, quadruplicate cultures were prepared against a 
range of 5 ganglioside concentrations. These concentrations were 1, 0.1, 0.05, 0.01 
and 0.005 ng/ml. The stimulation index (SI) was determined by the formula: 
SI=(mean c.p.m. of quadruplicate, ganglioside-containing wells)/(mean c.p.m. of 24 
control wells, without antigen). A positive proliferative response for a test subject’s 
cells was scored if the cells responded to the ganglioside tested at any 1 of the 5 
concentrations with an SI 2.0. 
Statistical analysis 
Percentages of individuals making a positive proliferative response to gangliosides 
were compared using the 2 test with Yates’ correction applied as required. Mean SI 
values were compared using analysis of variance (ANOVA) to compare all the test 
groups simultaneously, followed by Student’s t test to compare pairs of groups. A 
comparison was deemed to show statistical significance if P 0.05. 
Results 
The characteristics of the patients with MS, the healthy subjects and the patients with 
other CNS diseases are shown in Table 1. The percentages of individuals in each 
subject group with a SI 2.0 were determined for each ganglioside and compared by 
2 analysis (Fig. 2). The percentage of patients with primary progressive MS with a 
SI 2.0 for GM3 (32.3%) was significantly higher than the percentages of healthy 
subjects (14.0%) and patients with other CNS diseases (4.2%), but the percentage for 
patients with secondary progressive MS (22.2%) was not. The corresponding 
percentage for patients with relapsing-remitting MS (30.0%) was significantly higher 
than for patients with other CNS diseases but not significantly higher than for healthy 
subjects. As a combined group, patients with MS had a significantly higher 
percentage of individuals with a SI 2.0 for GM3 (28.6%) than did healthy subjects 
(P=0.048) or patients with other CNS diseases (P=0.024). For GQ1b, the percentage 
of patients with primary progressive MS with a SI 2.0 (34.5%) was also significantly 
higher than the percentages of healthy subjects (8.0%), patients with other CNS 
diseases (0.0%) and patients with relapsing-remitting MS (10.0%; P=0.028), but the 
corresponding percentages for patients with relapsing-remitting MS (10.0%) and 
secondary progressive MS (14.8%) were not significantly increased. Increased T cell 
reactivity (SI 2.0) to GM3 or GQ1b occurred significantly more often in patients 
with primary progressive MS (48.4%) than in healthy subjects (18.0%) and patients 
with other CNS diseases (4.2%). T cell reactivity to the other gangliosides was not 
significantly increased in any of the three groups of MS patients.  
Table 1. Characteristics of MS patients and control subjects  
 
RR-MS: relapsing-remitting MS, SP-MS: secondary progressive MS, PP-MS: primary progressive MS, 
OCD: other CNS diseases. 
 
Fig. 2. Percentages of patients with relapsing-remitting MS (RR-MS), patients with secondary 
progressive MS (SP-MS), patients with primary progressive MS (PP-MS), healthy control subjects 
(HC) and patients with other CNS diseases (OCD) responding with SI 2.0 to specific gangliosides. 
The P values for the comparison of the responses of the five groups together (5×2) and the P values for 
the comparisons of the pairs of groups ( 2 analysis) are shown directly below the ganglioside to which 
they refer. S, sulphatide. 
The mean maximum SI±SE for GM3 and GQ1b for each subject group is shown in 
Table 2. For GM3 the mean maximum SI for patients with primary progressive MS 
(2.05±0.30) was significantly higher than for healthy subjects (1.45±0.11) and for 
patients with other CNS diseases (1.27±0.09); it was also significantly higher for 
patients with relapsing-remitting MS (1.87±0.20) and for patients with secondary 
progressive MS (1.71±0.19) than for patients with other CNS diseases, but not 
significantly higher than for healthy subjects. As a combined group, patients with MS 
had a significantly higher mean maximum SI for GM3 (1.88±0.13) than did healthy 
subjects (P=0.035) and patients with other CNS diseases (P=0.025). For GQ1b, the 
mean maximum SI for patients with primary progressive MS (1.97±0.33) was 
significantly higher than for healthy subjects (1.36±0.11) and for patients with 
relapsing-remitting MS (1.31±0.10) but not significantly higher than for patients with 
other CNS diseases (1.25±0.08). HLA-DR typing of the patients with primary 
progressive MS did not reveal any association between T cell reactivity to GM3 or 
GQ1b and HLA-DR type. 
Table 2. Mean maximum stimulation index (SI±SE) of peripheral blood mononuclear cells from 
relapsing-remitting MS (RR-MS) patients, secondary progressive MS (SP-MS) patients, primary 
progressive MS (PP-MS) patients, healthy controls (HC) and patients with other CNS diseases (OCD) 
 
ANOVA was used to compare RR-MS patients, SP-MS patients, PP-MS patients, healthy controls and 
patients with other CNS diseases, simultaneously; for GM3, P=0.036: for GQ1b, P=0.029. Student’s t 
test was used to compare pairs of groups; significant P values are given adjacent to brackets linking 
pairs. 
Discussion 
The cause of MS is unclear but there is increasing evidence that it is an autoimmune 
disease.22, 23 We have previously shown that patients with relapsing-remitting or 
secondary progressive MS have increased peripheral blood T cell proliferative 
responses to two overlapping myelin proteolipid protein (PLP) peptides, PLP184–199 
and PLP190–209.24 This region of PLP is immunodominant in humans 25 and is 
encephalitogenic in mice of different genetic backgrounds. 26 Furthermore, 
longitudinal studies in these patients have shown an increased frequency of surges of 
circulating T cell reactivity to this region of PLP, which partly correlate with disease 
activity. 27 These findings suggest that the increased T cell response to the 184–209 
region of PLP may be pathogenic in relapsing-remitting and secondary progressive 
MS. In contrast, patients with primary progressive MS did not have increased T cell 
reactivity to this region of PLP or to any of the other myelin antigens studied. 24 This 
raised the possibility that the main target antigens in primary progressive MS are not 
myelin antigens but are perhaps axonal antigens. 1 
The present study has shown that patients with primary progressive MS have 
increased circulating T cell reactivity to gangliosides GM3 and GQ1b. The increased 
immune reactivity to GM3 and GQ1b in primary progressive MS may contribute to 
axonal damage or may be secondary to it. The fact that the anti-GM3 and anti-GQ1b 
immunoreactivity is significantly higher in patients with primary progressive MS than 
in patients with CNS axonal damage due to other neurological diseases indicates that 
the immunoreactivity is not secondary to the axonal damage and that it may be 
pathogenic. Indeed the T cell reactivity against gangliosides tended to be lower in 
patients with other CNS diseases than in healthy subjects, as we have previously 
reported for T cell reactivity to myelin basic protein.24 It should be noted that the 
proportion of primary progressive MS patients with increased T cell reactivity to 
GM3 and/or GQ1b in the present study may be an underestimate, as it is possible that 
the level of anti-ganglioside T cell reactivity in MS may fluctuate, as we have 
previously demonstrated for T cell reactivity against the 184–209 region of PLP. 27 At 
present it is unclear whether the increased T cell reactivity to GM3 and GQ1b in 
primary progressive MS is directed to separate antigenic epitopes or to a common 
moiety present in GM3 and GQ1b and perhaps other unstudied gangliosides. 
The paucity of recent studies of T cell reactivity against gangliosides in MS has 
probably been partly due to the lack of knowledge of the molecular mechanisms by 
which T cells recognize lipid and glycolipid antigens. This has been in striking 
contrast to the well understood presentation of peptide antigens to T cell receptors by 
major histocompatibility complex (MHC) class I and class II molecules. Recently, 
however, the mechanism of presentation of lipid and glycolipid antigens to T cells has 
been elucidated. These antigens are bound via their acyl chains in the deep 
hydrophobic groove of the MHC-like CD1 molecule so that their hydrophilic 
components are positioned for highly specific interactions with T cell antigen 
receptors.28 
The increased T cell reactivity to GM3 fits with our previously reported finding of 
increased circulating anti-GM3 antibodies in primary progressive MS 12; we did not 
measure anti-GQ1b antibodies in that study. The present study also suggests that 
patients with relapsing-remitting or secondary progressive MS have increased T cell 
reactivity to GM3, whereas our previous study found anti-GM3 antibodies to be 
normal in relapsing-remitting MS and increased in secondary progressive MS, 
although less so than in primary progressive disease. Acarin et al. 11 also found 
elevated serum antiganglioside (anti-GM1, anti-asialo GM1 and anti-GD1a) antibody 
levels significantly more frequently in patients with primary progressive MS than in 
those with relapsing-remitting MS or secondary progressive MS. 
Definite evidence that autoimmune responses against gangliosides are pathogenic in 
human disease remains elusive, although there is much circumstantial evidence to 
support this proposal. For example, increased levels of anti-GM1 antibodies occur in 
patients with the Guillain–Barre syndrome subsequent to Campylobacter jejuni 
enteritis 29 and in those with multifocal motor neuropathy. 30 Anti-GQ1b antibodies 
are elevated in patients with the Miller Fisher syndrome of ophthalmoplegia, ataxia 
and areflexia, 31 and increased anti-GD1a antibodies are associated with the acute 
motor axonal neuropathy subtype of the Guillain–Barre syndrome. 32 Furthermore, the 
induction of experimental sensory ataxic neuropathy in rabbits by immunization with 
GD1b3 proves that antiganglioside responses can be pathogenic. 
In conclusion, our present finding of increased circulating T cell reactivity to GM3 
and GQ1b in primary progressive MS raises the possibility that ganglioside-specific T 
cells may contribute to the pathogenesis of axonal damage in this form of MS. 
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